|
1
|
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
|
N Engl J Med
|
2011
|
28.99
|
|
2
|
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
|
N Engl J Med
|
2015
|
13.90
|
|
3
|
Scientific evidence underlying the ACC/AHA clinical practice guidelines.
|
JAMA
|
2009
|
13.69
|
|
4
|
Ethical and scientific implications of the globalization of clinical research.
|
N Engl J Med
|
2009
|
11.42
|
|
5
|
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
N Engl J Med
|
2003
|
10.57
|
|
6
|
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
|
J Am Coll Cardiol
|
2007
|
10.19
|
|
7
|
The ClinicalTrials.gov results database--update and key issues.
|
N Engl J Med
|
2011
|
9.83
|
|
8
|
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
|
JAMA
|
2004
|
9.74
|
|
9
|
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
|
N Engl J Med
|
2004
|
9.13
|
|
10
|
Sertraline treatment of major depression in patients with acute MI or unstable angina.
|
JAMA
|
2002
|
8.28
|
|
11
|
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
|
JAMA
|
2006
|
7.81
|
|
12
|
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
|
N Engl J Med
|
2013
|
7.09
|
|
13
|
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
|
N Engl J Med
|
2005
|
6.86
|
|
14
|
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
|
Circulation
|
2007
|
6.78
|
|
15
|
Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.
|
JAMA
|
2005
|
6.10
|
|
16
|
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
|
JAMA
|
2005
|
5.93
|
|
17
|
Effect of valsartan on the incidence of diabetes and cardiovascular events.
|
N Engl J Med
|
2010
|
5.46
|
|
18
|
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery.
|
N Engl J Med
|
2009
|
5.19
|
|
19
|
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.
|
JAMA
|
2004
|
5.11
|
|
20
|
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
|
Lancet
|
2002
|
5.04
|
|
21
|
Critical issues in peripheral arterial disease detection and management: a call to action.
|
Arch Intern Med
|
2003
|
4.72
|
|
22
|
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).
|
J Am Coll Cardiol
|
2002
|
4.64
|
|
23
|
What clinicians should know about the QT interval.
|
JAMA
|
2003
|
4.45
|
|
24
|
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.
|
N Engl J Med
|
2002
|
4.42
|
|
25
|
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
|
N Engl J Med
|
2010
|
4.38
|
|
26
|
Compliance with results reporting at ClinicalTrials.gov.
|
N Engl J Med
|
2015
|
4.17
|
|
27
|
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
|
Circulation
|
2012
|
4.10
|
|
28
|
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.
|
Circulation
|
2006
|
3.96
|
|
29
|
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II.
|
Ann Intern Med
|
2005
|
3.83
|
|
30
|
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).
|
Circulation
|
2002
|
3.80
|
|
31
|
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.
|
Circulation
|
2007
|
3.62
|
|
32
|
Evolution of adverse changes in stored RBCs.
|
Proc Natl Acad Sci U S A
|
2007
|
3.58
|
|
33
|
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
|
J Am Coll Cardiol
|
2009
|
3.54
|
|
34
|
Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials.
|
JAMA
|
2005
|
3.51
|
|
35
|
2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.
|
J Am Coll Cardiol
|
2011
|
3.37
|
|
36
|
Cardiorenal interactions: insights from the ESCAPE trial.
|
J Am Coll Cardiol
|
2008
|
3.35
|
|
37
|
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.
|
Kidney Int
|
2008
|
3.34
|
|
38
|
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
|
JAMA
|
2002
|
3.24
|
|
39
|
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
|
Am Heart J
|
2008
|
3.02
|
|
40
|
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
|
N Engl J Med
|
2002
|
3.01
|
|
41
|
The role of academic health science systems in the transformation of medicine.
|
Lancet
|
2009
|
2.98
|
|
42
|
Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
|
JAMA
|
2006
|
2.92
|
|
43
|
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
|
JAMA
|
2004
|
2.89
|
|
44
|
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov.
|
JAMA Intern Med
|
2013
|
2.86
|
|
45
|
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.
|
Circulation
|
2005
|
2.86
|
|
46
|
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
|
Lancet Neurol
|
2012
|
2.77
|
|
47
|
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
Circulation
|
2011
|
2.72
|
|
48
|
Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).
|
Circ Heart Fail
|
2008
|
2.69
|
|
49
|
Lessons learned from recent cardiovascular clinical trials: Part I.
|
Circulation
|
2002
|
2.57
|
|
50
|
Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.
|
Circulation
|
2011
|
2.52
|
|
51
|
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
|
N Engl J Med
|
2009
|
2.49
|
|
52
|
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial.
|
J Am Coll Cardiol
|
2007
|
2.47
|
|
53
|
International differences in evolution of early discharge after acute myocardial infarction.
|
Lancet
|
2004
|
2.47
|
|
54
|
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
|
JAMA
|
2004
|
2.46
|
|
55
|
Randomized clinical trials--removing unnecessary obstacles.
|
N Engl J Med
|
2013
|
2.43
|
|
56
|
Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.
|
Eur J Heart Fail
|
2007
|
2.39
|
|
57
|
Reengineering the national clinical and translational research enterprise: the strategic plan of the National Clinical and Translational Science Awards Consortium.
|
Acad Med
|
2010
|
2.38
|
|
58
|
2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
|
J Am Coll Cardiol
|
2011
|
2.37
|
|
59
|
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
|
Eur Heart J
|
2011
|
2.31
|
|
60
|
Economic return of clinical trials performed under the pediatric exclusivity program.
|
JAMA
|
2007
|
2.28
|
|
61
|
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
|
JACC Cardiovasc Imaging
|
2008
|
2.24
|
|
62
|
Early statin initiation and outcomes in patients with acute coronary syndromes.
|
JAMA
|
2002
|
2.23
|
|
63
|
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
|
Hypertension
|
2007
|
2.22
|
|
64
|
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
|
Circulation
|
2002
|
2.20
|
|
65
|
Sensible approaches for reducing clinical trial costs.
|
Clin Trials
|
2008
|
2.20
|
|
66
|
Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes.
|
Crit Care Med
|
2010
|
2.19
|
|
67
|
Sex differences in mortality following acute coronary syndromes.
|
JAMA
|
2009
|
2.17
|
|
68
|
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease.
|
JAMA
|
2005
|
2.17
|
|
69
|
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
2.17
|
|
70
|
An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
|
Am J Med
|
2002
|
2.12
|
|
71
|
Relationship between depressive symptoms and long-term mortality in patients with heart failure.
|
Am Heart J
|
2007
|
2.12
|
|
72
|
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events.
|
Am J Med
|
2002
|
2.09
|
|
73
|
Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials.
|
Am J Med
|
2005
|
2.08
|
|
74
|
Risk stratification after hospitalization for decompensated heart failure.
|
J Card Fail
|
2004
|
2.04
|
|
75
|
Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses.
|
Circulation
|
2004
|
2.04
|
|
76
|
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.
|
J Am Coll Cardiol
|
2007
|
2.03
|
|
77
|
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
|
Circulation
|
2010
|
2.00
|
|
78
|
Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes.
|
Circulation
|
2012
|
1.99
|
|
79
|
Changing preferences for survival after hospitalization with advanced heart failure.
|
J Am Coll Cardiol
|
2008
|
1.96
|
|
80
|
Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report.
|
Psychosom Med
|
2006
|
1.96
|
|
81
|
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.
|
Am J Cardiol
|
2005
|
1.96
|
|
82
|
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial.
|
Eur Heart J
|
2007
|
1.95
|
|
83
|
Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn.
|
Lancet
|
2002
|
1.93
|
|
84
|
Metabolic syndrome: definition, pathophysiology, and mechanisms.
|
Am Heart J
|
2005
|
1.88
|
|
85
|
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes.
|
Circulation
|
2002
|
1.88
|
|
86
|
Traversing the valley of death: a guide to assessing prospects for translational success.
|
Sci Transl Med
|
2009
|
1.81
|
|
87
|
2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
Circulation
|
2013
|
1.81
|
|
88
|
2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
J Am Coll Cardiol
|
2013
|
1.76
|
|
89
|
Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs.
|
Health Aff (Millwood)
|
2008
|
1.74
|
|
90
|
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial.
|
J Card Fail
|
2006
|
1.72
|
|
91
|
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.
|
Kidney Int
|
2009
|
1.72
|
|
92
|
Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure).
|
J Am Coll Cardiol
|
2013
|
1.70
|
|
93
|
Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV.
|
Ann Thorac Surg
|
2008
|
1.69
|
|
94
|
Reducing the costs of phase III cardiovascular clinical trials.
|
Am Heart J
|
2005
|
1.69
|
|
95
|
A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension.
|
Proc Natl Acad Sci U S A
|
2005
|
1.67
|
|
96
|
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
|
Circulation
|
2007
|
1.67
|
|
97
|
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
|
Arch Intern Med
|
2006
|
1.66
|
|
98
|
Pediatric antihypertensive trial failures: analysis of end points and dose range.
|
Hypertension
|
2008
|
1.65
|
|
99
|
Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference?
|
Circulation
|
2007
|
1.64
|
|
100
|
The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure.
|
J Card Fail
|
2011
|
1.63
|
|
101
|
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
|
Circulation
|
2003
|
1.63
|
|
102
|
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone.
|
Am J Cardiol
|
2002
|
1.60
|
|
103
|
Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank).
|
Am J Cardiol
|
2002
|
1.60
|
|
104
|
Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease.
|
Am Heart J
|
2012
|
1.59
|
|
105
|
Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy.
|
Circulation
|
2003
|
1.59
|
|
106
|
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes.
|
Eur Heart J
|
2006
|
1.59
|
|
107
|
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
|
Circulation
|
2005
|
1.59
|
|
108
|
High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients.
|
Hepatology
|
2011
|
1.59
|
|
109
|
Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial.
|
Am Heart J
|
2011
|
1.58
|
|
110
|
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
|
Am Heart J
|
2004
|
1.58
|
|
111
|
Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes.
|
J Am Coll Cardiol
|
2005
|
1.58
|
|
112
|
Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow.
|
J Am Coll Cardiol
|
2012
|
1.56
|
|
113
|
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction.
|
Eur J Heart Fail
|
2010
|
1.55
|
|
114
|
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
|
Eur Heart J
|
2004
|
1.55
|
|
115
|
Prognostic value of anxiety and depression in patients with chronic heart failure.
|
Circulation
|
2004
|
1.55
|
|
116
|
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
|
Circulation
|
2014
|
1.54
|
|
117
|
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
|
Eur Heart J
|
2013
|
1.53
|
|
118
|
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
|
JAMA
|
2005
|
1.52
|
|
119
|
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction.
|
Crit Care Med
|
2011
|
1.50
|
|
120
|
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
|
Circulation
|
2006
|
1.48
|
|
121
|
Multifaceted intervention to promote beta-blocker use in heart failure.
|
Am Heart J
|
2006
|
1.48
|
|
122
|
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
|
J Am Coll Cardiol
|
2008
|
1.48
|
|
123
|
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT).
|
Eur Heart J
|
2009
|
1.48
|
|
124
|
A comparison of phenotype definitions for diabetes mellitus.
|
J Am Med Inform Assoc
|
2013
|
1.47
|
|
125
|
Economic effects of beta-blocker therapy in patients with heart failure.
|
Am J Med
|
2004
|
1.46
|
|
126
|
Lessons learned from a clinical trial.
|
Circulation
|
2004
|
1.46
|
|
127
|
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
|
Circulation
|
2011
|
1.46
|
|
128
|
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
|
Int J Cardiol
|
2009
|
1.45
|
|
129
|
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
|
JAMA
|
2004
|
1.44
|
|
130
|
Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).
|
Am J Cardiol
|
2002
|
1.44
|
|
131
|
Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score.
|
J Am Coll Cardiol
|
2010
|
1.44
|
|
132
|
Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations.
|
Am Heart J
|
2002
|
1.43
|
|
133
|
Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft.
|
Circulation
|
2006
|
1.43
|
|
134
|
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.
|
J Am Coll Cardiol
|
2003
|
1.43
|
|
135
|
Selection of surgical or percutaneous coronary intervention provides differential longevity benefit.
|
Ann Thorac Surg
|
2006
|
1.42
|
|
136
|
Antidepressant use, depression, and survival in patients with heart failure.
|
Arch Intern Med
|
2008
|
1.42
|
|
137
|
Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease.
|
J Am Soc Nephrol
|
2003
|
1.42
|
|
138
|
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
|
Heart Rhythm
|
2006
|
1.41
|
|
139
|
Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure?
|
Am J Cardiol
|
2004
|
1.41
|
|
140
|
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.
|
J Am Coll Cardiol
|
2003
|
1.41
|
|
141
|
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
|
J Clin Hypertens (Greenwich)
|
2012
|
1.40
|
|
142
|
Lessons learned from clinical trials: a roundtable discussion.
|
Crit Pathw Cardiol
|
2003
|
1.40
|
|
143
|
Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial.
|
Am Heart J
|
2005
|
1.39
|
|
144
|
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.
|
Catheter Cardiovasc Interv
|
2002
|
1.39
|
|
145
|
TRENDS IN THE CARE AND OUTCOMES OF MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES, 2002-2011.
|
Endocr Pract
|
2016
|
1.38
|
|
146
|
Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial.
|
J Am Soc Nephrol
|
2005
|
1.37
|
|
147
|
Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters.
|
Ann Thorac Surg
|
2008
|
1.37
|
|
148
|
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.
|
J Am Coll Cardiol
|
2006
|
1.37
|
|
149
|
Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction.
|
Circulation
|
2009
|
1.36
|
|
150
|
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes.
|
Eur Heart J
|
2007
|
1.35
|
|
151
|
Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory.
|
J Am Med Inform Assoc
|
2013
|
1.35
|
|
152
|
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Circulation
|
2004
|
1.33
|
|
153
|
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
|
J Invasive Cardiol
|
2003
|
1.33
|
|
154
|
Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial.
|
Circ Heart Fail
|
2008
|
1.31
|
|
155
|
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study.
|
Curr Control Trials Cardiovasc Med
|
2001
|
1.30
|
|
156
|
Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study.
|
Am Heart J
|
2010
|
1.29
|
|
157
|
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.
|
Am J Med
|
2003
|
1.28
|
|
158
|
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
|
J Am Heart Assoc
|
2013
|
1.26
|
|
159
|
Geographic health information systems: a platform to support the 'triple aim'.
|
Health Aff (Millwood)
|
2013
|
1.26
|
|
160
|
A historical perspective on clinical trials innovation and leadership: where have the academics gone?
|
JAMA
|
2011
|
1.25
|
|
161
|
Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience.
|
Ann Emerg Med
|
2002
|
1.25
|
|
162
|
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
|
Am Heart J
|
2008
|
1.24
|
|
163
|
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
|
Circulation
|
2010
|
1.24
|
|
164
|
Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
|
Circulation
|
2004
|
1.24
|
|
165
|
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
|
J Am Coll Cardiol
|
2013
|
1.23
|
|
166
|
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.
|
Am Heart J
|
2012
|
1.22
|
|
167
|
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
|
Eur J Heart Fail
|
2006
|
1.22
|
|
168
|
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
|
Am Heart J
|
2005
|
1.20
|
|
169
|
Depression and ischemic heart disease: what have we learned so far and what must we do in the future?
|
Am Heart J
|
2005
|
1.18
|
|
170
|
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes.
|
Am Heart J
|
2006
|
1.17
|
|
171
|
Systematic adjudication of myocardial infarction end-points in an international clinical trial.
|
Curr Control Trials Cardiovasc Med
|
2001
|
1.17
|
|
172
|
Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers.
|
J Am Coll Cardiol
|
2006
|
1.16
|
|
173
|
Lessons learned from recent cardiovascular clinical trials: Part II.
|
Circulation
|
2002
|
1.16
|
|
174
|
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
|
Eur Heart J
|
2008
|
1.15
|
|
175
|
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
|
Am J Cardiol
|
2007
|
1.14
|
|
176
|
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
|
Am J Cardiol
|
2010
|
1.13
|
|
177
|
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
|
Circulation
|
2002
|
1.13
|
|
178
|
Prognostic significance of elevated troponin I after percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2002
|
1.12
|
|
179
|
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.
|
Am Heart J
|
2013
|
1.12
|
|
180
|
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years.
|
Int J Cardiol
|
2012
|
1.12
|
|
181
|
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
|
Am Heart J
|
2005
|
1.12
|
|
182
|
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
|
Crit Pathw Cardiol
|
2009
|
1.11
|
|
183
|
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
|
J Am Coll Cardiol
|
2003
|
1.11
|
|
184
|
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
|
Am Heart J
|
2008
|
1.10
|
|
185
|
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry.
|
Am Heart J
|
2006
|
1.10
|
|
186
|
Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?
|
Hypertension
|
2004
|
1.10
|
|
187
|
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
|
Circulation
|
2005
|
1.10
|
|
188
|
Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents.
|
PLoS One
|
2008
|
1.09
|
|
189
|
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
|
Ann Thorac Surg
|
2007
|
1.09
|
|
190
|
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
|
Am Heart J
|
2013
|
1.09
|
|
191
|
Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countries.
|
Circulation
|
2010
|
1.08
|
|
192
|
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
|
Am Heart J
|
2002
|
1.07
|
|
193
|
The Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis (MURDOCK) Study Community Registry and Biorepository.
|
Am J Transl Res
|
2012
|
1.07
|
|
194
|
A review of dyspnea in acute heart failure syndromes.
|
Am Heart J
|
2010
|
1.06
|
|
195
|
Forging stronger partnerships between academic health centers and patient-driven organizations.
|
Acad Med
|
2013
|
1.06
|
|
196
|
Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting.
|
Am J Cardiol
|
2010
|
1.05
|
|
197
|
Safety monitoring of drugs receiving pediatric marketing exclusivity.
|
Pediatrics
|
2008
|
1.05
|
|
198
|
Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery.
|
Circulation
|
2012
|
1.05
|
|
199
|
The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records.
|
Am J Transl Res
|
2012
|
1.05
|
|
200
|
Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management.
|
Am Heart J
|
2002
|
1.05
|
|
201
|
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome.
|
Am Heart J
|
2008
|
1.04
|
|
202
|
Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction.
|
Am J Med
|
2006
|
1.04
|
|
203
|
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
|
Eur Heart J
|
2009
|
1.03
|
|
204
|
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
|
Eur Heart J
|
2009
|
1.03
|
|
205
|
ST2 and mortality in non-ST-segment elevation acute coronary syndrome.
|
Am Heart J
|
2010
|
1.03
|
|
206
|
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
|
Eur J Heart Fail
|
2003
|
1.02
|
|
207
|
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
|
JACC Cardiovasc Interv
|
2008
|
1.02
|
|
208
|
Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004.
|
Am Heart J
|
2005
|
1.01
|
|
209
|
Usefulness of the Duke Sudden Cardiac Death risk score for predicting sudden cardiac death in patients with angiographic (>75% narrowing) coronary artery disease.
|
Am J Cardiol
|
2009
|
1.01
|
|
210
|
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
|
Am Heart J
|
2010
|
1.01
|
|
211
|
Cardiovascular disease and chronic kidney disease: insights and an update.
|
Am Heart J
|
2004
|
1.00
|
|
212
|
Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues.
|
Am Heart J
|
2008
|
1.00
|
|
213
|
Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF.
|
Circ Heart Fail
|
2013
|
1.00
|
|
214
|
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
|
BMJ
|
2013
|
1.00
|
|
215
|
Data and safety monitoring boards: academic credit where credit is due?
|
JAMA
|
2013
|
1.00
|
|
216
|
Association of depression and survival in patients with chronic heart failure over 12 Years.
|
Psychosomatics
|
2012
|
0.99
|
|
217
|
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
|
Am Heart J
|
2003
|
0.99
|
|
218
|
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
|
Am Heart J
|
2010
|
0.99
|
|
219
|
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2004
|
0.98
|
|
220
|
Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial.
|
Card Electrophysiol Rev
|
2003
|
0.98
|
|
221
|
International variation in the use of evidence-based medicines for acute coronary syndromes.
|
Eur Heart J
|
2003
|
0.98
|
|
222
|
Incidence and predictors of sudden cardiac death in patients with diastolic heart failure.
|
J Cardiovasc Electrophysiol
|
2007
|
0.97
|
|
223
|
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.
|
Circulation
|
2004
|
0.97
|
|
224
|
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
|
Am Heart J
|
2004
|
0.97
|
|
225
|
Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy.
|
Am Heart J
|
2004
|
0.96
|
|
226
|
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome.
|
Clin J Am Soc Nephrol
|
2009
|
0.96
|
|
227
|
Time-dependent predictors of primary cardiac arrest in patients with acute myocardial infarction.
|
Am J Cardiol
|
2003
|
0.96
|
|
228
|
Techniques and benefits of multiple internal mammary artery bypass at 20 years of follow-up.
|
Ann Thorac Surg
|
2007
|
0.96
|
|
229
|
American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy?
|
J Am Coll Cardiol
|
2011
|
0.96
|
|
230
|
Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial.
|
Am Heart J
|
2009
|
0.96
|
|
231
|
Public reporting of quality measures what are we trying to accomplish?
|
J Am Coll Cardiol
|
2009
|
0.96
|
|
232
|
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF.
|
Eur J Heart Fail
|
2012
|
0.95
|
|
233
|
Renal function, concomitant medication use and outcomes following acute coronary syndromes.
|
Nephrol Dial Transplant
|
2005
|
0.95
|
|
234
|
Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study).
|
Am J Cardiol
|
2004
|
0.95
|
|
235
|
Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
0.95
|
|
236
|
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.95
|
|
237
|
Safety and transparency of pediatric drug trials.
|
Arch Pediatr Adolesc Med
|
2009
|
0.95
|
|
238
|
International variation in invasive care of the elderly with acute coronary syndromes.
|
Eur Heart J
|
2006
|
0.95
|
|
239
|
Is old blood bad blood?
|
Am Heart J
|
2010
|
0.95
|
|
240
|
Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure.
|
Eur J Heart Fail
|
2002
|
0.95
|
|
241
|
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.
|
Circulation
|
2002
|
0.94
|
|
242
|
Publication or presentation of results from multicenter clinical trials: evidence from an academic medical center.
|
Am Heart J
|
2007
|
0.94
|
|
243
|
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
|
Stroke
|
2014
|
0.94
|
|
244
|
Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes.
|
Circulation
|
2003
|
0.93
|
|
245
|
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
|
Circ Heart Fail
|
2013
|
0.93
|
|
246
|
Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals.
|
Am Heart J
|
2008
|
0.93
|
|
247
|
Cardiovascular disease on a global scale: defining the path forward for research and practice.
|
Eur Heart J
|
2007
|
0.92
|
|
248
|
Left ventricular assessment in myocardial infarction: the VALIANT registry.
|
Arch Intern Med
|
2005
|
0.92
|
|
249
|
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes.
|
Am Heart J
|
2007
|
0.92
|
|
250
|
Rescuing clinical trials in the United States and beyond: a call for action.
|
Am Heart J
|
2013
|
0.92
|
|
251
|
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
|
Am Heart J
|
2010
|
0.91
|
|
252
|
Part I: Identifying holes in the safety net.
|
Am Heart J
|
2004
|
0.91
|
|
253
|
The economic returns of pediatric clinical trials of antihypertensive drugs.
|
Am Heart J
|
2008
|
0.91
|
|
254
|
Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial.
|
Am Heart J
|
2005
|
0.91
|
|
255
|
Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries.
|
Am Heart J
|
2002
|
0.91
|
|
256
|
Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease.
|
Am J Cardiol
|
2005
|
0.90
|
|
257
|
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT.
|
Am Heart J
|
2004
|
0.90
|
|
258
|
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.
|
Am J Med
|
2002
|
0.90
|
|
259
|
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death.
|
Am Heart J
|
2007
|
0.90
|
|
260
|
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
|
J Am Coll Cardiol
|
2006
|
0.90
|
|
261
|
Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report.
|
Ann Behav Med
|
2006
|
0.90
|
|
262
|
Postmarket evaluation of breakthrough technologies.
|
Am Heart J
|
2008
|
0.90
|
|
263
|
Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis.
|
Cardiology
|
2002
|
0.89
|
|
264
|
Aspirin dose and six-month outcome after an acute coronary syndrome.
|
J Am Coll Cardiol
|
2004
|
0.89
|
|
265
|
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
|
Catheter Cardiovasc Interv
|
2007
|
0.89
|
|
266
|
Determining the most appropriate components for a composite clinical trial outcome.
|
Am Heart J
|
2008
|
0.89
|
|
267
|
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction.
|
Eur Heart J
|
2006
|
0.89
|
|
268
|
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
|
Am Heart J
|
2006
|
0.89
|
|
269
|
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial.
|
Heart
|
2010
|
0.89
|
|
270
|
Part II: Sealing holes in the safety net.
|
Am Heart J
|
2004
|
0.89
|
|
271
|
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry.
|
Am Heart J
|
2009
|
0.88
|
|
272
|
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups.
|
Heart
|
2006
|
0.88
|
|
273
|
Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial.
|
Am Heart J
|
2013
|
0.88
|
|
274
|
Portfolio of clinical research in adult cardiovascular disease as reflected in ClinicalTrials.gov.
|
J Am Heart Assoc
|
2013
|
0.88
|
|
275
|
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
|
Am J Cardiol
|
2005
|
0.88
|
|
276
|
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction.
|
Am Heart J
|
2006
|
0.88
|
|
277
|
Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000.
|
Am J Cardiol
|
2003
|
0.88
|
|
278
|
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
|
Am J Nephrol
|
2013
|
0.88
|
|
279
|
Statin use and sex-specific stroke outcomes in patients with vascular disease.
|
Stroke
|
2006
|
0.88
|
|
280
|
Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery.
|
J Thorac Cardiovasc Surg
|
2008
|
0.87
|
|
281
|
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial).
|
Am J Cardiol
|
2006
|
0.87
|
|
282
|
Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes.
|
Am J Med
|
2005
|
0.87
|
|
283
|
Knowledge deficits related to the QT interval could affect patient safety.
|
Ann Noninvasive Electrocardiol
|
2003
|
0.87
|
|
284
|
The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
|
J Thromb Thrombolysis
|
2002
|
0.87
|
|
285
|
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
|
JAMA
|
2002
|
0.87
|
|
286
|
Economic impact of drug-eluting stents on hospital systems: a disease-state model.
|
Am Heart J
|
2004
|
0.86
|
|
287
|
Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.
|
Circulation
|
2004
|
0.86
|
|
288
|
A survey of health care practitioners' knowledge of the QT interval.
|
J Gen Intern Med
|
2005
|
0.86
|
|
289
|
High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization.
|
J Card Fail
|
2008
|
0.86
|
|
290
|
Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure.
|
Am J Cardiol
|
2008
|
0.86
|
|
291
|
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
|
Ann Intern Med
|
2013
|
0.86
|
|
292
|
Relationship of the time interval between cardiac catheterization and elective coronary artery bypass surgery with postprocedural acute kidney injury.
|
Circulation
|
2011
|
0.86
|
|
293
|
An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial.
|
Am J Med
|
2003
|
0.86
|
|
294
|
AHA scientific statement: practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized electrocardiology and the American Association of Critical-Care Nurses.
|
J Cardiovasc Nurs
|
2005
|
0.86
|
|
295
|
Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study.
|
Eur J Heart Fail
|
2012
|
0.86
|
|
296
|
Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome.
|
Clin Biochem
|
2013
|
0.86
|
|
297
|
Metabolic syndrome: evaluation of pathological and therapeutic outcomes.
|
Am Heart J
|
2005
|
0.86
|
|
298
|
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
|
Am Heart J
|
2002
|
0.86
|
|
299
|
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis.
|
Am J Cardiol
|
2011
|
0.85
|
|
300
|
Rivaroxaban, an oral direct factor Xa inhibitor.
|
Expert Opin Investig Drugs
|
2008
|
0.85
|
|
301
|
Long-term clinical outcomes following coronary stenting.
|
Arch Intern Med
|
2008
|
0.85
|
|
302
|
Delivering heart failure disease management in 3 tertiary care centers: key clinical components and venues of care.
|
Am Heart J
|
2008
|
0.85
|
|
303
|
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
|
J Am Heart Assoc
|
2014
|
0.85
|
|
304
|
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
|
Circ Heart Fail
|
2013
|
0.85
|
|
305
|
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
|
Int J Cardiol
|
2008
|
0.85
|
|
306
|
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 3: diagnosis and treatment of acute cardiac ischemia: gender issues.
|
Circulation
|
2004
|
0.85
|
|
307
|
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
|
Am Heart J
|
2013
|
0.85
|
|
308
|
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
0.85
|
|
309
|
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends.
|
J Am Coll Cardiol
|
2013
|
0.84
|
|
310
|
Changing the model of care for patients with acute coronary syndromes.
|
Am Heart J
|
2003
|
0.84
|
|
311
|
Diets and clinical coronary events: the truth is out there.
|
Circulation
|
2003
|
0.84
|
|
312
|
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy.
|
Am Heart J
|
2005
|
0.84
|
|
313
|
An academic-health service partnership in nursing: lessons from the field.
|
J Nurs Scholarsh
|
2012
|
0.84
|
|
314
|
Negative trials in nephrology: what can we learn?
|
Kidney Int
|
2008
|
0.84
|
|
315
|
Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry.
|
Crit Pathw Cardiol
|
2009
|
0.84
|
|
316
|
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2005
|
0.84
|
|
317
|
Racial differences are seen in blood pressure response to fosinopril in hypertensive children.
|
Am Heart J
|
2006
|
0.84
|
|
318
|
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
|
Am Heart J
|
2007
|
0.84
|
|
319
|
Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015.
|
J Am Heart Assoc
|
2015
|
0.84
|
|
320
|
Antithrombotics in acute coronary syndromes.
|
J Am Coll Cardiol
|
2009
|
0.84
|
|
321
|
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes.
|
J Am Coll Cardiol
|
2002
|
0.84
|
|
322
|
Performance measures have a major effect on cardiovascular outcomes: a review.
|
Am J Med
|
2007
|
0.84
|
|
323
|
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.83
|
|
324
|
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
|
Eur Heart J
|
2008
|
0.83
|
|
325
|
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
|
Am Heart J
|
2004
|
0.83
|
|
326
|
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
|
Circulation
|
2007
|
0.83
|
|
327
|
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients.
|
Eur Heart J Acute Cardiovasc Care
|
2013
|
0.83
|
|
328
|
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.
|
Circulation
|
2012
|
0.83
|
|
329
|
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Am Heart J
|
2008
|
0.83
|
|
330
|
A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.
|
Can J Cardiol
|
2004
|
0.83
|
|
331
|
Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.
|
J Thromb Thrombolysis
|
2003
|
0.83
|
|
332
|
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial.
|
Am J Cardiol
|
2006
|
0.82
|
|
333
|
Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF).
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.82
|
|
334
|
Safety of placebo controls in pediatric hypertension trials.
|
Hypertension
|
2008
|
0.82
|
|
335
|
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
|
J Gen Intern Med
|
2008
|
0.82
|
|
336
|
Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.82
|
|
337
|
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy.
|
Am J Med
|
2011
|
0.82
|
|
338
|
Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction.
|
Am Heart J
|
2004
|
0.82
|
|
339
|
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
|
Circulation
|
2002
|
0.82
|
|
340
|
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
|
Am Heart J
|
2005
|
0.82
|
|
341
|
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial.
|
Eur Heart J
|
2006
|
0.82
|
|
342
|
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
|
Cardiovasc Ther
|
2010
|
0.82
|
|
343
|
Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease.
|
J Thorac Cardiovasc Surg
|
2009
|
0.82
|
|
344
|
The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time?
|
Am Heart J
|
2013
|
0.81
|
|
345
|
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
|
Catheter Cardiovasc Interv
|
2010
|
0.81
|
|
346
|
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome.
|
Am Heart J
|
2008
|
0.81
|
|
347
|
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005.
|
Am Heart J
|
2008
|
0.81
|
|
348
|
Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.
|
Am J Cardiol
|
2003
|
0.81
|
|
349
|
Missing signposts on the roadmap to quality: a call to improve medication adherence indicators in data collection for population research.
|
Front Pharmacol
|
2013
|
0.81
|
|
350
|
Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
|
JACC Cardiovasc Interv
|
2012
|
0.81
|
|
351
|
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).
|
Am J Cardiol
|
2008
|
0.81
|
|
352
|
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes.
|
Am J Cardiol
|
2007
|
0.81
|
|
353
|
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
|
JAMA
|
2002
|
0.81
|
|
354
|
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
|
Am J Kidney Dis
|
2012
|
0.81
|
|
355
|
Time to reperfusion in acute myocardial infarction. It is time to reduce it!
|
J Electrocardiol
|
2007
|
0.81
|
|
356
|
Seeking the optimal aspirin dose in acute coronary syndromes.
|
Am J Cardiol
|
2002
|
0.81
|
|
357
|
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
|
JAMA
|
2005
|
0.80
|
|
358
|
Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF).
|
Am Heart J
|
2008
|
0.80
|
|
359
|
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy.
|
Am Heart J
|
2007
|
0.80
|
|
360
|
Slowing the progression of diabetic nephropathy and its cardiovascular consequences.
|
Am Heart J
|
2004
|
0.80
|
|
361
|
Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock.
|
Am J Cardiol
|
2007
|
0.80
|
|
362
|
Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability.
|
J Am Coll Cardiol
|
2002
|
0.80
|
|
363
|
Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict.
|
Am Heart J
|
2008
|
0.80
|
|
364
|
Framework for Curating and Applying Data Elements within Continuing Use Data: A Case Study from the Durham Diabetes Coalition.
|
AMIA Jt Summits Transl Sci Proc
|
2013
|
0.80
|
|
365
|
Translation of academic discovery into societal benefit: proposal for a balanced approach--part 1.
|
Am J Med
|
2003
|
0.80
|
|
366
|
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).
|
Am J Cardiol
|
2008
|
0.80
|
|
367
|
Randomized clinical trials--removing obstacles.
|
N Engl J Med
|
2013
|
0.80
|
|
368
|
Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR.
|
Nephrol Dial Transplant
|
2012
|
0.80
|
|
369
|
An evidence-based score to detect prevalent peripheral artery disease (PAD).
|
Vasc Med
|
2012
|
0.80
|
|
370
|
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.
|
J Interv Cardiol
|
2003
|
0.80
|
|
371
|
Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial.
|
Am Heart J
|
2005
|
0.80
|
|
372
|
Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF.
|
J Card Fail
|
2013
|
0.79
|
|
373
|
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
|
Eur Heart J
|
2013
|
0.79
|
|
374
|
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
|
Am J Cardiol
|
2004
|
0.79
|
|
375
|
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
|
J Thromb Thrombolysis
|
2011
|
0.79
|
|
376
|
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis.
|
J Am Coll Cardiol
|
2011
|
0.79
|
|
377
|
Coronary drug-eluting stent development: issues in trial design.
|
Am Heart J
|
2005
|
0.79
|
|
378
|
Stenting or surgery: an opportunity to do it right.
|
J Am Coll Cardiol
|
2005
|
0.79
|
|
379
|
24-hour ambulatory blood pressure monitoring.
|
Am Heart J
|
2006
|
0.79
|
|
380
|
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
|
Am J Cardiol
|
2008
|
0.79
|
|
381
|
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
|
Am Heart J
|
2006
|
0.79
|
|
382
|
Cardiovascular research in India: a perspective.
|
Am Heart J
|
2011
|
0.79
|
|
383
|
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes.
|
J Thromb Thrombolysis
|
2004
|
0.79
|
|
384
|
Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
|
Am J Cardiol
|
2007
|
0.79
|
|
385
|
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials.
|
Eur Heart J
|
2007
|
0.79
|
|
386
|
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.
|
BMJ Open
|
2012
|
0.79
|
|
387
|
Clinical trial issues in weight-loss therapy.
|
Am Heart J
|
2006
|
0.78
|
|
388
|
How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
|
Health Aff (Millwood)
|
2006
|
0.78
|
|
389
|
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
|
Am Heart J
|
2005
|
0.78
|
|
390
|
Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty.
|
J Am Coll Cardiol
|
2004
|
0.78
|
|
391
|
Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes.
|
Eur Heart J
|
2005
|
0.78
|
|
392
|
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
|
Stroke
|
2013
|
0.78
|
|
393
|
A virtuous cycle to improve hypertension outcomes at a national level: linking public health and individualized medicine.
|
Hypertension
|
2008
|
0.78
|
|
394
|
Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy.
|
J Am Coll Cardiol
|
2002
|
0.78
|
|
395
|
Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial).
|
Am J Cardiol
|
2007
|
0.78
|
|
396
|
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial.
|
Am Heart J
|
2013
|
0.78
|
|
397
|
Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials.
|
Heart Fail Clin
|
2011
|
0.78
|
|
398
|
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
|
Am Heart J
|
2004
|
0.78
|
|
399
|
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
|
Circulation
|
2013
|
0.77
|
|
400
|
The need for academic leadership in full-spectrum translational research.
|
Clin Transl Sci
|
2011
|
0.77
|
|
401
|
Check it, change it: a community-based intervention to improve blood pressure control.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.77
|
|
402
|
Evaluating the impact of public health notification: Duke clopidogrel experience.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.77
|
|
403
|
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
Am Heart J
|
2006
|
0.77
|
|
404
|
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
|
J Am Coll Cardiol
|
2004
|
0.77
|
|
405
|
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes.
|
Eur Heart J
|
2006
|
0.77
|
|
406
|
A new look at an old therapy.
|
JAMA
|
2012
|
0.77
|
|
407
|
Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries.
|
Am Heart J
|
2002
|
0.77
|
|
408
|
Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications.
|
Am Heart J
|
2002
|
0.77
|
|
409
|
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
|
Am J Cardiol
|
2002
|
0.77
|
|
410
|
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.
|
Eur Heart J Acute Cardiovasc Care
|
2013
|
0.77
|
|
411
|
Patient-reported frequency of taking aspirin in a population with coronary artery disease.
|
Am J Cardiol
|
2002
|
0.77
|
|
412
|
Predicting significant coronary artery disease in patients with left ventricular dysfunction.
|
Am Heart J
|
2006
|
0.77
|
|
413
|
Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada.
|
Am Heart J
|
2003
|
0.77
|
|
414
|
Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)?
|
Circulation
|
2004
|
0.76
|
|
415
|
Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation.
|
Circulation
|
2002
|
0.76
|
|
416
|
The trouble with ischemia.
|
Am Heart J
|
2012
|
0.76
|
|
417
|
Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
|
Am J Cardiol
|
2002
|
0.76
|
|
418
|
Outcomes of second revascularization procedures after stent implantation.
|
J Med Syst
|
2008
|
0.76
|
|
419
|
Attribution of causality in clinical research: an important element for learning health systems.
|
Am Heart J
|
2013
|
0.76
|
|
420
|
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
|
Am J Cardiol
|
2008
|
0.76
|
|
421
|
The relationship between meteorological conditions and index acute coronary events in a global clinical trial.
|
Int J Cardiol
|
2013
|
0.76
|
|
422
|
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes.
|
Am J Med
|
2004
|
0.76
|
|
423
|
Careers for clinician investigators.
|
Circulation
|
2009
|
0.76
|
|
424
|
Simple principles of clinical trials remain powerful.
|
JAMA
|
2005
|
0.76
|
|
425
|
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
|
Am Heart J
|
2013
|
0.76
|
|
426
|
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).
|
Am J Cardiol
|
2003
|
0.75
|
|
427
|
Impact of on-site cardiac interventional facilities on management and outcome of patients with acute coronary syndromes.
|
Can J Cardiol
|
2003
|
0.75
|
|
428
|
Conflicting information about conflict of interest.
|
J Am Coll Cardiol
|
2013
|
0.75
|
|
429
|
Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?
|
J Am Coll Cardiol
|
2006
|
0.75
|
|
430
|
Angiographic profiles in courage.
|
Circ Cardiovasc Qual Outcomes
|
2009
|
0.75
|
|
431
|
Watching the WATCH trial: the role of sponsors and data monitoring committees.
|
J Card Fail
|
2004
|
0.75
|
|
432
|
Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?
|
J Am Coll Cardiol
|
2008
|
0.75
|
|
433
|
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
|
Am J Hypertens
|
2013
|
0.75
|
|
434
|
When can noninferior be superior? The multidimensional nature of clinical decision-making calls for innovative approaches to clinical trials.
|
J Am Coll Cardiol
|
2010
|
0.75
|
|
435
|
Biomarker bonanza?
|
J Am Coll Cardiol
|
2010
|
0.75
|
|
436
|
Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?
|
Ann Noninvasive Electrocardiol
|
2010
|
0.75
|
|
437
|
Biomarkers, putative surrogates, surrogates, and decision making.
|
Circ Cardiovasc Imaging
|
2013
|
0.75
|
|
438
|
Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above?
|
JAMA
|
2006
|
0.75
|
|
439
|
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?
|
Eur Heart J
|
2013
|
0.75
|
|
440
|
Postmarket surveillance and returned product analysis: success but not transparency.
|
Heart Rhythm
|
2013
|
0.75
|
|
441
|
The coxib story: some lessons and more questions.
|
Am J Cardiol
|
2002
|
0.75
|
|
442
|
The benefits of moving quality to a national level.
|
Am Heart J
|
2008
|
0.75
|
|
443
|
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”.
|
Circulation
|
2013
|
0.75
|
|
444
|
Prediabetes and the risk of diabetes.
|
Lancet
|
2012
|
0.75
|
|
445
|
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?
|
J Interv Cardiol
|
2013
|
0.75
|
|
446
|
Postmenopausal hormone use in women with acute coronary syndromes.
|
J Womens Health (Larchmt)
|
2004
|
0.75
|
|
447
|
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials.
|
Am Heart J
|
2007
|
0.75
|
|
448
|
Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy.
|
Am J Cardiol
|
2005
|
0.75
|
|
449
|
No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial.
|
Am Heart J
|
2007
|
0.75
|
|
450
|
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
|
Cardiology
|
2002
|
0.75
|
|
451
|
Practitioner acceptance of the dofetilide risk-management program.
|
Pharmacotherapy
|
2002
|
0.75
|
|
452
|
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.75
|
|
453
|
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
|
Am Heart J
|
2004
|
0.75
|
|
454
|
Task force 2: Investigator participation in clinical research.
|
J Am Coll Cardiol
|
2004
|
0.75
|
|
455
|
Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
|
Can J Cardiol
|
2004
|
0.75
|
|
456
|
Evaluation of the dofetilide risk-management program.
|
Am Heart J
|
2003
|
0.75
|
|
457
|
Translation of academic discovery into societal benefit: proposal for a balanced approach--part 2.
|
Am J Med
|
2003
|
0.75
|
|
458
|
Establishing a framework for improving the quality of clinical and translational research.
|
J Clin Oncol
|
2012
|
0.75
|
|
459
|
Working group 1: How to increase the output of cardiologists.
|
J Am Coll Cardiol
|
2004
|
0.75
|
|
460
|
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
|
J Thromb Thrombolysis
|
2012
|
0.75
|
|
461
|
The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience.
|
Am Heart J
|
2006
|
0.75
|
|
462
|
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Am Heart J
|
2006
|
0.75
|
|
463
|
Anticoagulation in acute cardiac care in patients with chronic kidney disease.
|
Am Heart J
|
2003
|
0.75
|
|
464
|
Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial.
|
Am Heart J
|
2010
|
0.75
|
|
465
|
Introduction. Quality of health care.
|
Am Heart J
|
2004
|
0.75
|
|
466
|
Improving communication of drug risks to prevent patient injury: proceedings of a workshop.
|
Pharmacoepidemiol Drug Saf
|
2003
|
0.75
|
|
467
|
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
|
J Interv Cardiol
|
2007
|
0.75
|
|
468
|
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
|
Am Heart J
|
2013
|
0.75
|
|
469
|
A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
|
Am J Cardiol
|
2013
|
0.75
|
|
470
|
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
0.75
|
|
471
|
Towards a new order in cardiovascular medicine: re-engineering through global collaboration.
|
Eur Heart J
|
2010
|
0.75
|
|
472
|
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
|
Int J Cardiol
|
2012
|
0.75
|
|
473
|
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.
|
Am J Med
|
2003
|
0.75
|
|
474
|
There is a role for industry-sponsored education in cardiology.
|
Circulation
|
2010
|
0.75
|
|
475
|
An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.
|
J Thromb Thrombolysis
|
2002
|
0.75
|
|
476
|
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
|
Am J Cardiol
|
2009
|
0.75
|
|
477
|
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
|
Eur Heart J
|
2004
|
0.75
|
|
478
|
In search of the efficient way to medical decisions: the case of acute heart failure syndrome.
|
Am Heart J
|
2012
|
0.75
|
|
479
|
Publication policy, informed consent, and the randomized clinical trial.
|
Am Heart J
|
2002
|
0.75
|
|
480
|
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb.
|
Eur Heart J
|
2008
|
0.75
|
|
481
|
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
|
Am Heart J
|
2007
|
0.75
|
|
482
|
Where's the flap?
|
J Cardiovasc Magn Reson
|
2006
|
0.75
|
|
483
|
Research education and training in otolaryngology: meeting summary and research opportunities.
|
Otolaryngol Head Neck Surg
|
2006
|
0.75
|
|
484
|
Disease management in healthcare organizations: results of in-depth interviews with disease management decision makers.
|
Am J Manag Care
|
2002
|
0.75
|
|
485
|
Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction.
|
Am Heart J
|
2011
|
0.75
|
|
486
|
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis.
|
Crit Pathw Cardiol
|
2010
|
0.75
|
|
487
|
TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention.
|
Curr Opin Cardiol
|
2002
|
0.75
|
|
488
|
Marketing drugs too early in testing.
|
Science
|
2006
|
0.75
|
|
489
|
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes.
|
J Am Coll Cardiol
|
2013
|
0.75
|
|
490
|
Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF.
|
Eur J Heart Fail
|
2015
|
0.75
|
|
491
|
Perspective: Autonomic care systems for hospitalized patients.
|
Acad Med
|
2009
|
0.75
|
|
492
|
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.
|
Am Heart J
|
2011
|
0.75
|